Seletalisib (UCB5857)
| Disease area studied | Abbreviated title | Phase | Study ID | Registry database | Study results | Plain language summary | Publication (if available) |
|---|---|---|---|---|---|---|---|
| Sjogren´s Syndrome | A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjorgen's Syndrome | Phase 2 |
SS0004
Terminated |
NCT02610543 2014-004523-51 |
LINK
|
Juarez M., Diaz N., Johnston G.I., Nayar S., Payne A. et al. Rheumatology 2021, 60(3):1364-1375 | |
| APDS | An Open-Label, Exploratory, Multicenter, Extension Study to Evaluate the Long-Term Safety, Tolerability, Pharmacokinetics and Efficacy of UCB5857 in Subjects with Activated Phosphoinositide 3 Kinase (PI3K) Delta Syndrome (APDS) | Phase 3 |
APD003
Terminated |
2015-005541-30 |
LINK
|